Biosig Technologies Inc

BioSig Technologies, Inc. is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. Its product PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intra-cardiac signals for patients undergoing electrophysiology procedures. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Westport, CT, Aug. 24, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that it has installed a second evaluation system at the Cleveland Clinic. The additional installation will support the medical center's clinical evaluation of the PURE EP™ System and expand physician access to the Company's signal processing technology.

BioSig Places Second PURE EP™ System For Evaluation at Cleveland Clinic a Leading Medical Center of Excellence

Leading Medical Center of Excellence Physician will discuss integrating the PURE EP™ System into their practice and procedural workflow Leading Medical Center of Excellence Physician will discuss integrating the PURE EP™ System into their practice and procedural workflow

BioSig's Cardiac Signal Processing Technology To Be Featured at Kansas City Heart Rhythm Symposium 2022

Westport, CT, Aug. 16, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that it is seeing positive momentum from the growth of its sales pipeline, and expects to see an increase in enterprise adoption of its PURE EP™ System  in the coming months.

BioSig Sees Positive Momentum from Sales Pipeline Growth

Led by Dhanunjaya DJ Lakkireddy, MD., the study will investigate expanded applications for the signals acquired by BioSig's PURE EP(T.M.) System Led by Dhanunjaya DJ Lakkireddy, MD., the study will investigate expanded applications for the signals acquired by BioSig's PURE EP(T.M.) System

BioSig Announces Physician-Initiated Research Protocol at The Kansas City Heart Rhythm Institute

BioSig Technologies Inc has announced that Kansas City Heart Institute at Overland Park Regional Medical Center in Kansas City, USA, has signed a purchase agreement to acquire its PURE EP System. Following its evaluation of BioSig's PURE EP System, Overland Park Regional Medical Center (OPRMC) has signed an agreement to purchase the technology under the terms of the company's new program.

BioSig Technologies says Kansas City Heart Institute signs purchase agreement for its PURE EP System

Westport, CT, July 07, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that Kansas City Heart Institute at Overland Park Regional Medical Center in Kansas City, U.S. has signed a purchase agreement to acquire its PURE EP(T.M.) System.

BioSig Announces Purchase Agreement with Kansas City Heart Rhythm Institute at Overland Park Regional Medical Center

BioSig Technologies Inc has earned a reiterated ‘Outperform' rating and $4 price target from analysts at Noble Capital days after pricing a public offering that generated proceeds of $2.9 million.  The offering was “[a] bit unexpected, timing-wise, but supports PURE EP commercialization,” the firm wrote.

BioSig Technologies gets repeat 'Outperform' tag, $4 price target from Noble Capital

Westport, CT, June 29, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced the closing and funding of its previously announced best efforts underwritten public offering.

BioSig Announces Closing of Public Offering of Common Stock

Westport, CT, June 24, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced pricing of its previously-announced best efforts underwritten public offering of up to 4,666,667 shares of its common stock, $0.001 par value per share, at a price to the public of $0.75 per share. The gross proceeds to BioSig from this offering are expected to be $3,500,000.25, before deducting the underwriting discount and other estimated offering expenses payable by BioSig. The offering is expected to close on June 28, 2022, subject to customary closing conditions.

BioSig Announces Pricing of Public Offering of Common Stock

BioSig Technologies, Inc. (NASDAQ:BSGM) has said it intends to offer shares of its common stock in a "best efforts" underwritten public offering. BioSig said it intends to use the net proceeds from the offering for the continuation of commercialization activities related to the PURE EP System, including additional support for organizational development, to fund working capital, and for general corporate purposes and other capital expenditures.

BioSig Technologies says it intends to offer shares of its common stock in a "best efforts" underwritten public offering

Westport, CT, June 23, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it intends to offer shares of its common stock in a “best efforts” underwritten public offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

BioSig Announces Proposed Public Offering of Common Stock

BioSig Technologies, Inc. (NASDAQ:BSGM) said it has entered into an evaluation agreement for its PURE EP System with Cleveland Clinic, its first following the induction of a new commercialization team to accelerate the process from product evaluation to adoption. The medical technology company said Cleveland Clinic, a non-profit multi-specialty academic medical center, will participate in a 60-day evaluation of BioSig's signal processing platform.

BioSig Technologies enters deal for Cleveland Clinic to evaluate its PURE EP signal processing platform

Despite numerous positive updates around its PURE EP segment, the market is agnostic in directional movements on the chart. Whilst the muddy waters on its PURE EP economics have been somewhat cleared, many uncertainties remain.

BioSig: PURE EP Economics Trade Exhausted

BioSig Technologies Inc plans to kick off a national commercial launch campaign for its PURE EP System on July 1, 2022 following multiple initiatives to accelerate its transition from limited market release to nationwide availability. BioSig has more than 30 qualified leads ahead of the launch and to-date, more than 73 physicians have completed over 2,200 patient cases with the PURE EP System, the company said.

BioSig targets July 1 to launch national PURE EP commercial campaign

Westport, CT, May 26, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced the rollout of the Company's national commercial launch campaign.

BioSig Advances its PURE™ System Commercial Launch to Medical Centers Nationwide

The Company's flagship technology to be featured during a two-day educational conference that draws the world's top cardiac electrophysiology experts The Company's flagship technology to be featured during a two-day educational conference that draws the world's top cardiac electrophysiology experts

BioSig's PURE EP™ System to be Featured During EPLive 2022

BioSig Technologies Inc drew an ‘Outperform' rating from Noble Capital, which noted that "stronger commercialization efforts” are underway for the company's PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP systems after the first quarter. In a note to clients, Noble Capital analysts observed that BioSig recorded no PURE EP unit sales during the quarter, which was “below our expectations of three units”.

BioSig maintains ‘Outperform' rating from Noble Capital as "stronger commercialization efforts” underway for its PURE EP system

BioSig Technologies, Inc. (NASDAQ:BSGM) CEO Kenneth Londoner said the company has made great strides on multiple fronts as it accelerates commercial momentum for developing a national installed base of its PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP systems. In a letter to shareholders, the company reported recent highlights including that the PURE EP system has now completed over 2,200 patient cases with 75 physicians at 17 hospitals across the United States, the strengthening of its management team, and the launch of its NOVA-5 software which offers greater customization and smarter workflows with the aim of further driving clinical adoption.

BioSig Technologies CEO Kenneth Londoner says the company has made great strides as it accelerates commercial momentum for its PURE EP system

Westport, CT, May 11, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today issued a Letter to Shareholders providing highlights on the Company's recent developments and updates.

BioSig Technologies, Inc. Issues Shareholder Letter with Corporate Update on Recent Achievements

Company's conference program to include physician presentations and technology demonstrations, including features of its newly released PURE EP(TM) Nova-5 Software Company's conference program to include physician presentations and technology demonstrations, including features of its newly released PURE EP(TM) Nova-5 Software

BioSig to Present at Heart Rhythm 2022

Westport, CT, April 07, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, will be presenting at NobleCon18 - Noble Capital Markets' Eighteenth Annual Investor Conference at the Hard Rock Hotel & Casino, Hollywood, Florida on Wednesday, April 20, 2022 at 9:30 AM ET. Conference attendees will also have the opportuntity to meet BioSig management during breakout sessions scheduled for 1:00 PM ET on Wednesday April 20, 2022.

BioSig to Present at NobleCon18 Capital Markets Conference

BioSig Technologies Inc has announced a new partnership agreement with Summit Blue Capital for implementing a leasing and finance program for its PURE EP System. The Minneapolis-based Summit Blue Capital is a leader in equipment finance and leasing, as it offers tailored leasing and financing solutions for its partners and clients in industries such as healthcare, manufacturing, hospitality, technology solutions, and more.

BioSig Technologies partners with Summit Blue Capital to provide leasing and finance program for its PURE EP System

The leasing and finance program provides a non-recourse financial solution for PURE EP™ to improve purchase flexibility for U.S. hospitals The leasing and finance program provides a non-recourse financial solution for PURE EP™ to improve purchase flexibility for U.S. hospitals

BioSig Technologies, Inc. Partners with Summit Blue Capital to Provide Equipment Leasing Services

BioSig Technologies Inc has announced the completion of its previously announced underwritten public offering of 2,611,739 shares of its common stock at a price to the public of $1.15 per share for proceeds of $3 million. The company also said it has issued a cash warrant at $1.40, which if fully exercised will see the company receive another $3 million of cash proceeds.

BioSig Technologies completes its previously announced underwritten public offering for proceeds of $3 million

BioSig Technologies Inc announced that it has agreed to sell $3 million of its common stock and warrants to a family office, which the company said has deep expertise in small-cap emerging growth investing.  BioSig noted the net proceeds from the offering will be used to fund working capital and continue commercialization activities related to the PURE EP System.

News for Biosig Technologies Inc Stock (BSGM)